<DOC>
	<DOC>NCT00968617</DOC>
	<brief_summary>This study will define an effective starting dose for subcutaneous administration of MK2578 to correct anemia in erythropoiesis-stimulating agent (ESA)-naive patients with chronic kidney disease (CKD) who are not on dialysis while evaluating its safety.</brief_summary>
	<brief_title>A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>Patient is male or is a female who either cannot have children or who agrees to use appropriate contraceptive measures Patient has chronic kidney disease Patient is morbidly obese Patient has used another erythropoiesis (red blood cell formation) stimulating agent within 12 weeks of screening Patient will require dialysis during the study or is planning to have a kidney transplant within the next 6 months Patient has had a blood transfusion within 12 weeks of screening Patient has had major surgery within the past 12 weeks or plans to have surgery Patient has Human Immunodeficiency Virus (HIV) Patient has a history of diseases other than CKD known to cause anemia Patient has severe congestive heart failure Patient has history of malignant cancer, except certain skin or cervical cancers Patient has a history of grand mal seizures within the last 6 months Patient is pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Anemia</keyword>
</DOC>